Type your tag names separated by a space and hit enter

[Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].

Abstract

OBJECTIVE

The present review provides a brief introduction into the endocannabinoid system and discusses main strategies of pharmacological interventions.

METHOD

We have reviewed the literature relating to the endocannabinoid system and its pharmacology; both original and review articles written in English were considered.

DISCUSSION

Cannabinoids are a group of compounds present in Cannabis Sativa (hemp), such as Delta(9)-tetrahydrocannabinol, and their synthetic analogues. Research on their pharmacological profile led to the discovery of the endocannabinoid system in the mammalian brain. This system comprises at least two G-protein coupled receptors, CB(1) and CB(2), their endogenous ligands (endocannabinoids; e.g. the fatty acid derivatives anandamide and 2-arachydonoyl glycerol), and the enzymes responsible for endocannabinoid synthesis and catabolism. Endocannabinoids represent a class of neuromessengers, which are synthesized on demand and released from post-synaptic neurons to restrain the release of classical neurotransmitters from pre-synaptic terminals. This retrograde signalling modulates a variety of brain functions, including anxiety, fear and mood, whereby activation of CB(1) receptors was shown to exert anxiolytic-and antidepressant-like effects in preclinical studies.

CONCLUSION

Animal experiments suggest that drugs promoting endocannabinoid action may represent a novel strategy for the treatment of depression and anxiety disorders.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Programa de pós-graduação em Neurociências, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.

    ,

    Source

    MeSH

    Animals
    Anxiety Disorders
    Cannabinoid Receptor Agonists
    Cannabinoid Receptor Antagonists
    Cannabinoid Receptor Modulators
    Depression
    Endocannabinoids
    Humans
    Receptors, Cannabinoid
    Signal Transduction

    Pub Type(s)

    English Abstract
    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    por

    PubMed ID

    20512266

    Citation

    * When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?]. AU - Saito,Viviane M, AU - Wotjak,Carsten T, AU - Moreira,Fabrício A, PY - 2010/6/1/entrez PY - 2010/6/1/pubmed PY - 2011/2/4/medline SP - S7 EP - 14 JF - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JO - Braz J Psychiatry VL - 32 Suppl 1 N2 - OBJECTIVE: The present review provides a brief introduction into the endocannabinoid system and discusses main strategies of pharmacological interventions. METHOD: We have reviewed the literature relating to the endocannabinoid system and its pharmacology; both original and review articles written in English were considered. DISCUSSION: Cannabinoids are a group of compounds present in Cannabis Sativa (hemp), such as Delta(9)-tetrahydrocannabinol, and their synthetic analogues. Research on their pharmacological profile led to the discovery of the endocannabinoid system in the mammalian brain. This system comprises at least two G-protein coupled receptors, CB(1) and CB(2), their endogenous ligands (endocannabinoids; e.g. the fatty acid derivatives anandamide and 2-arachydonoyl glycerol), and the enzymes responsible for endocannabinoid synthesis and catabolism. Endocannabinoids represent a class of neuromessengers, which are synthesized on demand and released from post-synaptic neurons to restrain the release of classical neurotransmitters from pre-synaptic terminals. This retrograde signalling modulates a variety of brain functions, including anxiety, fear and mood, whereby activation of CB(1) receptors was shown to exert anxiolytic-and antidepressant-like effects in preclinical studies. CONCLUSION: Animal experiments suggest that drugs promoting endocannabinoid action may represent a novel strategy for the treatment of depression and anxiety disorders. SN - 1516-4446 UR - https://www.unboundmedicine.com/medline/citation/20512266/abstract/[Pharmacological_exploitation_of_the_endocannabinoid_system:_new_perspectives_for_the_treatment_of_depression_and_anxiety_disorders]_ L2 - http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462010000500004&lng=en&nrm=iso&tlng=en DB - PRIME DP - Unbound Medicine ER -